OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

Cannabis has long been a controversial substance, particularly within the world of professional sports, where its use has ...

Tobacco and coffee contain bioactive compounds that may reduce Parkinson's disease risk by targeting key pathways such as MAO ...

Ophthalmic diseases specialist Oculis Holding AG announced positive phase II data showing its serum-glucose corticoid ...

Oculis Holding ( (OCS) ) has issued an update. Oculis Holding has announced positive results from a Phase 2 trial for OCS-05, a potential first-in-class neuroprotective therapy for acute optic ...

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to ...

The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

Glaucoma is a progressive eye disorder characterized by fluid buildup inside the eye, causing ocular hypertension. By 2040, ...